Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma

被引:4
|
作者
Sasaki, Ken [1 ,3 ]
Tsuruda, Yusuke [1 ]
Shimonosono, Masataka [1 ]
Noda, Masahiro [1 ]
Uchikado, Yasuto [1 ]
Arigami, Takaaki [2 ]
Matsushita, Daisuke [1 ]
Mori, Shinichiro [1 ]
Nakajo, Akihiro [1 ]
Kurahara, Hiroshi [1 ]
Ohtsuka, Takao [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Surg Breast & Thyroid Surg, Kagoshima, Japan
[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Oncobiol Surg, Kagoshima, Japan
[3] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Surg Breast & Thyroid Surg, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan
关键词
Esophageal squamous cell carcinoma; docetaxel; cisplatin; 5-fluorouracil; neoadjuvant chemoradiotherapy; LOCALLY ADVANCED ESOPHAGEAL; PREOPERATIVE CHEMORADIOTHERAPY; PHASE-II; CANCER; CISPLATIN; CHEMOTHERAPY; DCF; THERAPY; SURGERY; TRIAL;
D O I
10.21873/anticanres.15884
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To further improve the prognosis of locally advanced esophageal cancer patients, investigating new perioperative treatment strategies is necessary. The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: We retrospectively reviewed 95 patients with ESCC who received CF-RT or DCF-RT followed by esophagectomy. The CF-RT group received chemotherapy consisting of two courses of CF repeated every 4 weeks. The DCF-RT group received chemotherapy consisting of two courses of DCF repeated every 2 weeks. A radiotherapy dose of 1.8-2 Gy was administered per session, up to a total of 40-41.4 Gy. Adverse events of neoadjuvant chemoradiotherapy, surgical outcomes, pathological responses, prognosis, and recurrence patterns were evaluated. Results: Both the CF-RT and DCF-RT groups had equivalent pathological complete response rates of the primary tumor at 31.6% and 38.6%, respectively. However, the DCF-RT group had significantly better 5-year disease-free survival and 5-year overall survival than (HR=0.50, 95%CI=0.26-0.97, p=0.0392) than the CF-RT group. Conclusion: DCF-RT may be a candidate neoadjuvant therapy for locally advanced ESCC.
引用
收藏
页码:3905 / 3911
页数:7
相关论文
共 50 条
  • [1] Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery
    Sugimura, Keijiro
    Miyata, Hiroshi
    Shinno, Naoki
    Ushigome, Hajime
    Asukai, Kei
    Yanagimoto, Yoshitomo
    Hasegawa, Shinnichiro
    Takahashi, Yusuke
    Yamada, Daisaku
    Yamamoto, Kazuyoshi
    Nishimura, Junichi
    Motoori, Masaaki
    Wada, Hiroshi
    Takahashi, Hidenori
    Yasui, Masayoshi
    Omori, Takeshi
    Ohue, Masayuki
    Yano, Masahiko
    [J]. ONCOLOGY, 2019, 97 (06) : 348 - 355
  • [2] Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma
    Miyawaki, Yutaka
    Nakajima, Yasuaki
    Kawada, Kenro
    Okada, Takuya
    Tokairin, Yutaka
    Kawano, Tatsuyuki
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [3] Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma
    Mitsuhiro Sugawara
    Chikatoshi Katada
    Natsuya Katada
    Kaoru Takahashi
    Katsuhiko Higuchi
    Shouko Komori
    Hiromitsu Moriya
    Hiromichi Ishiyama
    Keishi Yamashita
    Shinichi Sakuramoto
    Satoshi Tanabe
    Wasaburo Koizumi
    Kazuo Yago
    [J]. Esophagus, 2013, 10 : 65 - 69
  • [4] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma
    Sasaki, Ken
    Uchikado, Yasuto
    Omoto, Itaru
    Arigami, Takaaki
    Osako, Yusaku
    Noda, Masahiro
    Okumura, Hiroshi
    Maemura, Kosei
    Higashi, Ryutaro
    Yoshiura, Takashi
    Natsugoe, Shoji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 581 - 587
  • [5] Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma
    Sugawara, Mitsuhiro
    Katada, Chikatoshi
    Katada, Natsuya
    Takahashi, Kaoru
    Higuchi, Katsuhiko
    Komori, Shouko
    Moriya, Hiromitsu
    Ishiyama, Hiromichi
    Yamashita, Keishi
    Sakuramoto, Shinichi
    Tanabe, Satoshi
    Koizumi, Wasaburo
    Yago, Kazuo
    [J]. ESOPHAGUS, 2013, 10 (02) : 65 - 69
  • [6] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma
    Ken Sasaki
    Yasuto Uchikado
    Itaru Omoto
    Takaaki Arigami
    Yusaku Osako
    Masahiro Noda
    Hiroshi Okumura
    Kosei Maemura
    Ryutaro Higashi
    Takashi Yoshiura
    Shoji Natsugoe
    [J]. Cancer Chemotherapy and Pharmacology, 2019, 83 : 581 - 587
  • [7] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer
    Emi, Manabu
    Hihara, Jun
    Hamai, Yoichi
    Aoki, Yoshiro
    Okada, Morihito
    Kenjo, Masahiro
    Murakami, Yuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1499 - 1505
  • [8] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer
    Manabu Emi
    Jun Hihara
    Yoichi Hamai
    Yoshiro Aoki
    Morihito Okada
    Masahiro Kenjo
    Yuji Murakami
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1499 - 1505
  • [9] A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil
    Ui, Takashi
    Nagase, Michitaka
    Hosoya, Yoshinori
    Kurashina, Kentaro
    Haruta, Hidenori
    Zuiki, Toru
    Yasuda, Yoshikazu
    Ura, Takashi
    Muro, Kei
    Fujii, Hirofumi
    [J]. ESOPHAGUS, 2011, 8 (01) : 59 - 62
  • [10] A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil
    Takashi Ui
    Michitaka Nagase
    Yoshinori Hosoya
    Kentaro Kurashina
    Hidenori Haruta
    Toru Zuiki
    Yoshikazu Yasuda
    Takashi Ura
    Kei Muro
    Hirofumi Fujii
    [J]. Esophagus, 2011, 8 : 59 - 62